Document text
Principal Investigator: GUIRONG WANG
Organization: UPSTATE MEDICAL UNIVERSITY
Fiscal Year: 2022
Award: $244,500
Funding agency: National Institute of Allergy and Infectious Diseases
More than 4.8 million people have died due to coronavirus disease 2019 (COVID-19) in less than two years.
COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Morbidity and mortality following SARS-CoV-2 infection are predominantly due to a robust influx of inflammatory
cells and cytokines into the lungs resulting in acute lung injury (ALI) and acute respiratory distress syndrome
(ARDS). Individuals exhibited different degree of disease severity after SARS-CoV-2 infection. Human
Surfactant proteins A and D (hSP-A and hSP-D), two members of C-type lectin (surfactant collectin), are
pattern recognition proteins, and they play a critical role as a first-line host defense and innate immunity in the
mucosal surfaces of the lung and other organs. Our preliminary data and recent in vitro studies demonstrated
that hSP-A and hSP-D can bind to SARS-CoV-2 Spike protein and inhibit viral entry and replication in lung
epithelial cells. Interestingly, the genes of hSP-A and hSP-D are highly polymorphic, and several genetic variants
(alleles) for each of them have been identified in the general population. However, the mechanistic roles of hSP-
A and hSP-D genetic variants in the pathogenesis of COVID-19 are unknow. The long-term goal is to determine
the roles of hSP-A and hSP-D genetic variants in susceptibility and severity to SARS-CoV-2-induced ALI/ARDS
and to develop novel variant-specific therapeutic drug for the treatment of COVID-19. This proposal aims to
determine molecular interaction of surfactant collection and Spike protein, and define the mechanistic roles of
hSP-A and hSP-D genetic variants causing individual susceptibilities to COVID-19. Our central hypothesis is that
hSP-A and hSP-D genetic variants differentially influence susceptibility and severity to SARS-CoV-2-induced
ALI/ARDS by inhibiting SARS-CoV-2 infectivity and modulating mucosal innate immunity and pathophysiology.
Recently, we have generated a new double-humanized transgenic (double-hTG) mouse model, which
express human angiotensin-converting enzyme-2 (SARS-CoV-2 cognate receptor) and hSP-A or hSP-D genetic
variant. This double-hTG model provides us with a powerful tool to study the innate immune response and
mechanistic roles of hSP-A and hSP-D variants following SARS-CoV-2 infection. We propose two specific aims
to test our hypothesis: Aim 1: Study the interactions of hSP-A or hSP-D genetic variants with SARS-CoV-2 spike
protein and the inhibitory effect on viral entry and replication in lung epithelial cells. Aim 2: Define the differential
roles of hSP-A genetic variants in inhibiting viral infectivity and modulating SARS-CoV-2-induced ALI through
regulating TLRs/NF-kB/IFN signaling in a double-hTG mouse model. The proposal is strongly supported by our
preliminary data and available novel double-hTG model suitable for COVID-19 study. We expect that the
successful completion of the proposed studies will establish a novel COVID-19 murine model, and have a better
understanding of the innate immune roles of hSP-A and hSP-D in COVID-19 pathogenesis that is crucial to
develop novel immunomodulatory therapies and personalized medicine.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><ACE2><ARDS><Acute Lung Injury><Acute Pulmonary Injury><Acute Respiratory Distress><Acute Respiratory Distress Syndrome><Adult ARDS><Adult RDS><Adult Respiratory Distress Syndrome><Airway infections><Alleles><Allelomorphs><Amino Acids><Antibodies><B.1.617.2><Binding><C-Type Lectins><COVID-19><COVID-19 S protein><COVID-19 pathogenesis><COVID-19 predisposition><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 susceptibility><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID-19 vulnerability><COVID19><COVID19 S protein><COVID19 pathogenesis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 therapy><COVID19 treatment><COVID19 virus><CV-19><CV19><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Cessation of life><CoV-2><CoV2><Code><Coding System><Collagen><Collagenous Lectins><Collectins><Collection><Communicable Diseases><Coronavirus disease 2019 predisposition><Coronavirus disease 2019 susceptibility><Coronavirus disease 2019 vulnerability><Da Nang Lung><Data><Death><Delta variant><Development><Disease><Disease Outcome><Disorder><Drug Therapy><Dysfunction><Epithelial><Epithelial Cells><Exhibits><Functional disorder><GWA study><GWAS><Gene variant><General Population><General Public><Genes><Genetic Diversity><Genetic Polymorphism><Genetic Variation><Goals><Host Defense><Human><IFN><Immune><Immune Modulation Therapy><Immunes><Immunoglobulin Enhancer-Binding Protein><Immunomodulation><In Vitro><Individual><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Inflammatory><Innate Immune Response><Innate Immunity><Interdisciplinary Research><Interdisciplinary Study><Interferons><Intracellular Communication and Signaling><Investigation><Link><Lung><Lung Alveolar Epithelia><Lung Protein D><Lung Respiratory System><Mice><Mice Mammals><Microbe><Modeling><Modern Man><Molecular><Molecular Interaction><Molecular and Cellular Biology><Morbidity><Morbidity - disease rate><Mucosa><Mucosal Tissue><Mucous Membrane><Multidisciplinary Collaboration><Multidisciplinary Research><Murine><Mus><NF-kB><NF-kappa B><NF-kappaB><NFKB><Native Immunity><Natural Immunity><Non-Specific Immunity><Nonspecific Immunity><Nuclear><Nuclear Factor kappa B><Nuclear Transcription Factor NF-kB><Organ><Outcome><Pathogenesis><Patients><Pattern Recognition><Persons><Pharmacotherapy><Physiopathology><Play><Position><Positioning Attribute><Predisposed to COVID-19><Predisposed to SARS-CoV-2><Predisposed to Severe acute respiratory syndrome coronavirus 2><Predisposition><Proteins><Public Health><Pulmonary Surfactant Protein D><Pulmonary Surfactant-Associated Protein A><Pulmonary Surfactant-Associated Protein D><Receptor Protein><Reporting><Research><Respiratory Infections><Respiratory Tract Infections><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.617.2><SARS-CoV-2 S protein><SARS-CoV-2 delta><SARS-CoV-2 inhibitor><SARS-CoV-2 pathogenesis><SARS-CoV-2 predisposition><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 susceptibility><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 vulnerability><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SP-A Protein><SP-D><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 predisposition><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 susceptibility><Severe acute respiratory syndrome coronavirus 2 vulnerability><Severe acute respiratory syndrome related corona virus 2><Severities><Severity of illness><Shock Lung><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Stiff lung><Surface><Surfactant Protein A><Surfactant Protein D><Surfactant-Associated Glycoprotein D><Susceptibility><System><Techniques><Testing><Therapeutic><Transcription Factor NF-kB><Transgenic Organisms><United States><Variant><Variation><Viral><Viral Burden><Viral Load><Viral Load result><Wuhan coronavirus><after COVID-19 infection><after SARS-CoV-2 infection><after SARS-CoV2 infection><after severe acute respiratory distress syndrome CoV-2 infection><allele variant><allelic variant><alveolar epithelium><aminoacid><angiotensin converting enzyme 2><angiotensin converting enzyme II><base><biological signal transduction><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><block viral entry><carbohydrate structure><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 pathogenesis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 pathogenesis><coronavirus disease-19 virus><coronavirus infectious disease-19><cytokine><design><designing><developmental><disease phenotype><disease severity><drug treatment><following COVID-19 infection><following SARS-CoV-2 infection><following SARS-CoV2 infection><following severe acute respiratory distress syndrome CoV-2 infection><genetic variant><genome wide association><genome wide association scan><genome wide association studies><genome wide association study><genomewide association scan><genomewide association studies><genomewide association study><genomic variant><hCoV19><immune modulating therapies><immune modulation><immune modulatory therapies><immune regulation><immune-modulation treatment><immunologic reactivity control><immunomodulation therapy><immunomodulation treatment><immunomodulatory><immunomodulatory therapies><immunomodulatory therapy><immunomodulatory treatment><immunoregulation><immunoregulatory><in vivo><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><inhibit viral entry><innate immune function><innovate><innovation><innovative><kappa B Enhancer Binding Protein><member><mortality><mouse model><murine model><nCoV2><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><nuclear factor kappa beta><pathophysiology><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><polymorphism><post SARS-CoV-2 infection><predisposed to Coronavirus disease 2019><previous COVID-19 infection><previous SARS-CoV-2 infection><previous SARS-CoV2 infection><previous severe acute respiratory distress syndrome CoV-2 infection><prior COVID-19 infection><prior SARS-CoV-2 infection><prior SARS-CoV2 infection><prior severe acute respiratory distress syndrome CoV-2 infection><pulmonary><receptor><severe acute respiratory syndrome coronavirus 2 B.1.617.2><severe acute respiratory syndrome coronavirus 2 pathogenesis><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><social role><surfactant><susceptible to COVID-19><susceptible to Coronavirus disease 2019><susceptible to SARS-CoV-2><susceptible to Severe acute respiratory syndrome coronavirus 2><tool><transgenic><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><viral entry blocker><viral entry inhibitor><virology><wet lung><whole genome association analysis><whole genome association studies><whole genome association study>